Efavirenz contraindications: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) |
Gerald Chi (talk | contribs) mNo edit summary |
||
(One intermediate revision by one other user not shown) | |||
Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
== | ==Contraindications== | ||
===Hypersensitivity=== | ===Hypersensitivity=== | ||
SUSTIVA is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of this product. | SUSTIVA is contraindicated in patients with previously demonstrated clinically significant [[hypersensitivity]] (eg, [[Stevens-Johnson syndrome]], [[erythema multiforme]], or toxic skin eruptions) to any of the components of this product. | ||
===Contraindicated Drugs=== | ===Contraindicated Drugs=== | ||
For some drugs, competition for CYP3A by efavirenz could result in inhibition of their metabolism and create the potential for serious and/or life-threatening adverse reactions (eg, cardiac | For some drugs, competition for [[CYP3A]] by efavirenz could result in inhibition of their metabolism and create the potential for serious and/or life-threatening adverse reactions (eg, cardiac [[arrhythmia]]s, prolonged [[sedation]], or [[respiratory depression]]). Drugs that are contraindicated with SUSTIVA are listed in Table 2.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SUSTIVA (EFAVIRENZ) CAPSULE, GELATIN COATED SUSTIVA (EFAVIRENZ) CAPSULE, GELATIN COATED SUSTIVA (EFAVIRENZ) TABLET, FILM COATED [BRISTOL-MYERS SQUIBB PHARMA COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=32d6371e-ba56-4294-b732-6d43627c5c47 | publisher = | date = | accessdate = }}</ref> | ||
{| | {| |
Latest revision as of 06:17, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Contraindications
Hypersensitivity
SUSTIVA is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of this product.
Contraindicated Drugs
For some drugs, competition for CYP3A by efavirenz could result in inhibition of their metabolism and create the potential for serious and/or life-threatening adverse reactions (eg, cardiac arrhythmias, prolonged sedation, or respiratory depression). Drugs that are contraindicated with SUSTIVA are listed in Table 2.[1]
References
Adapted from the FDA Package Insert.